Bristol-Myers Squibb Company (BMY) is considered one of the best conservative stocks to buy now, emphasizing its leadership in cell therapy at a recent event. With 13,000 patients treated and extensive clinical data, the company sees significant opportunities in CAR-T treatments. Their lead gene therapy, Breyanzi, is approved to treat certain adult lymphomas.

BMY is a global biopharmaceutical company focused on innovative medicines for serious diseases like oncology and immunology. While BMY has investment potential, some believe AI stocks offer greater upside with less risk. For those interested in undervalued AI stocks, a report on the best short-term AI stock is available. No disclosures mentioned in the article.

Read more at Yahoo Finance: Bristol-Myers Squibb Company (BMY) to Capitalize on Cell Therapy Edge to Pursue CAR-T Treatment Opportunities